Tag: investment
-
Biopharma Secures $38.5 Million in Series D Funds
Chiasma Inc., a biopharmaceutical company in Jerusalem, Israel, has closed its $38.5 million series D funding round, the fourth cycle of financing after initial start-up. The round was led by by new investor Abingworth and current investor MPM Capital, with participation from current share holders 7 Med Health Ventures, ARCH Venture Partners, F3 Ventures, and…
-
University, Company to Collaborate on Cancer Imaging
Queen’s University in Belfast, Northern Ireland, U.K., is partnering with start-up company Cirdan Imaging Ltd., also in Northern Ireleand, to develop new imaging tools for the detection and treatment of cancer. As part of the deal, QUBIS Ltd., the university’s technology transfer subsidiary, will take an equity stake in Cirdan Imaging. The agreement involves research…
-
VC Funding Cut for U.S. Firms, Science Companies Take Hit
Venture capital investments in U.S.-based companies are down for the second quarter of 2012, with software and Internet companies favored over enterprises based on scientific discoveries. According to Dow Jones VentureSource, a financial industry research service, companies in the U.S. raised $8.1 billion in 863 deals during the second quarter of 2012, a nine percent…
-
Chronic Pain Technology Company Gains $3.5M Series B Funds
Neuros Medical Inc., a company in Cleveland developing a university-discovered electronic pain relief technology, says it raised $3.5 million in series B venture funds, the second round of financing after start-up. Boston Scientific and Glengary LLC led the round, with new investors RiverVest Venture Partners, LLC, Blue Tree Allied Angels, and ModelVest joining current investors…
-
Report: Business Research Funding Decline Impacts Innovation
A new report from the National Science Board, the governing body of the National Science Foundation, says declines in business R&D investment over the past decade, particularly during the recession of 2008-2009, are taking a toll on American innovation. The report, Research & Development, Innovation, and the Science and Engineering Workforce, also notes that reductions…
-
Renewable Chemicals Developer Raises $104M in Venture Funds
Elevance Renewable Sciences in Woodbridge, Illinois says it raised $104 million in its series E financing, the fifth round of funding after start-up. Lacustrine Limited, a subsidiary of Genting Berhad, based in Kuala Lumpur, Malaysia led the round with Total Energy Ventures International, based in Paris. Elevance produces specialty chemicals for personal care products, detergents,…
-
Venture Investors Increase First Half 2012 Fund Raising
Venture capital (VC) funds in Europe and the U.S. have increased their fund raising in the first half of 2012 by double-digit percentages, according to Dow-Jones LP Source, a financial industry research service. More fund raising by VCs indicates potentially more financing available for start-up companies liked those backed by venture investors. LP Source says…
-
Luminex Corp. Acquires Molecular Diagnostics Developer
Luminex Corporation, a maker of medical diagnostics technologies in Austin, Texas will acquire Hayward, California-based GenturaDx, a developer of genomic testing systems. The $50 million deal involves Luminex purchasing all outstanding shares in the privately-owned GenturaDx. Luminex develops and manufactures instruments, software, reagents, and assays used in clinical labs as well as in pharmaceutical, diagnostic,…
-
Memory Device Maker Secures $12.5 Million Venture Loan
Avalanche Technology, a developer of digital memory devices in Fremont, California has received a $12.5 million loan from Horizon Technology Finance Corporation in Farmington, Connecticut. Horizon Technology Finance calls the deal a venture loan, since the debt is secured by earlier venture capital and private equity financing. The funding is expected to support Avalanche Technology’s…
-
Bristol-Myers Squibb Buys Amylin, Expands AstraZenca Deal
The pharmaceutical company Bristol-Myers Squibb in Princeton, New Jersey will acquire diabetes drug maker Amylin Pharmaceuticals in San Diego, California for $31.00 per share or $5.3 billion. Bristol-Myers Squibb will also expand its current collaboration with pharmaceutical maker AstraZeneca in London developing diabetes drugs, using the assets acquired through Amylin. Amylin Pharmaceuticals is expected to…